Document Type

Article

Publication Date

2024

Abstract

Objective: Information is needed to guide the design of randomized controlled trials (RCTs) evaluating L-citrulline therapy for premature infants with pulmonary hypertension associated with bronchopulmonary dysplasia (BPD-PH). Based on our single-dose pharmacokinetic study, we evaluated the ability of a multi-dose enteral L-citrulline strategy to achieve a target trough steady-state L-citrulline plasma concentration and its tolerability in premature infants. Study design: Plasma L-citrulline concentrations were measured in six premature infants receiving 60 mg/kg L-citrulline every 6 h for 72 h before the first and last L-citrulline doses. L-citrulline concentrations were compared to concentration-time profiles from our previous study. Results: Target trough plasma L-citrulline concentrations were achieved in 2/6 subjects. No serious adverse events occurred. Conclusions: Multi-dose L-citrulline was well tolerated. These results will assist in the design of phase II RCTs evaluating L-citrulline dosage strategies to achieve target plasma L-citrulline concentrations in infants at risk for BPD-PH.

Comments

This work is licensed under CC BY 4.0 Creative Commons Attribution 4.0 License

DOI

10.1038/s41372-023-01809-y

PMCID

PMC10844094

Download


Included in

Pediatrics Commons

Share

COinS